Business Context and Reporting Period
This Form 8-K Current Report was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on March 25, 2021. The filing discloses a significant capital raising event involving the pricing of senior notes to fund a strategic acquisition.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company priced $2.525 billion in aggregate principal amount of senior unsecured notes.
- $1.525 billion of 0.737% Senior Notes due March 15, 2023.
- $1.000 billion of 2.700% Senior Notes due March 15, 2031.
- Net Proceeds: Estimated at approximately $2.51 billion after deducting underwriting discounts and offering expenses.
- Use of Proceeds: Intended to finance a portion of the proposed acquisition of the majority of Walgreens Boots Alliance, Inc.'s Alliance Healthcare businesses, pay related fees, and for general corporate purposes.
- Existing Debt Facilities: As of December 31, 2020, there were no borrowings outstanding under the multi-currency revolving credit facility. The subsidiary Amerisource Receivables Financial Corporation had $350 million outstanding under the receivables securitization facility.
Material Changes and Transaction Terms
The primary material change is the execution of an Underwriting Agreement with J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC, and Wells Fargo Securities, LLC. The closing of the sale of notes was expected on March 30, 2021.
Mandatory Redemption Clause: The offering is not contingent on the completion of the Alliance Healthcare acquisition. However, if the acquisition is not completed by January 6, 2022, or if the Share Purchase Agreement is terminated prior to that date (other than in connection with the consummation of the acquisition), the Notes are subject to mandatory redemption in whole at 101% of the aggregate principal amount plus accrued interest.
Outlook, Risks, and Management Commentary
Management expects to invest net proceeds in high-quality, short-term debt securities pending application for the acquisition. The filing includes extensive forward-looking statements regarding the risks associated with the transaction and the broader business environment.
- Acquisition Risks: Risks include failure to obtain regulatory approvals, integration difficulties, failure to achieve expected synergies, and disruption to business operations.
- Operational Risks: Factors include pharmaceutical pricing trends, regulatory changes (Medicare/Medicaid), opioid litigation, and the impact of COVID-19 on payment terms and operations.
- Financial Risks: Risks include interest rate fluctuations, foreign currency exchange rate fluctuations, and potential impairment of goodwill.
Investor Verification Checklist
- Verify the final closing date of the $2.525 billion note offering (expected March 30, 2021).
- Monitor the status of the proposed acquisition of Walgreens Boots Alliance's Alliance Healthcare businesses against the January 6, 2022, mandatory redemption deadline.
- Review the definitive Underwriting Agreement (Exhibit 1.1) for specific covenants and conditions.
- Assess the impact of the new debt load on the Company's leverage ratios and liquidity position.
- Track regulatory approval progress for the Alliance Healthcare acquisition.